- Home
- VSTM
VSTM
Verastem Inc.
as 10-29-2025 9:35am EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Upcoming Earnings Alert:
Get ready for potential market movements as Verastem Inc. VSTM prepares to release earnings report on 04 Nov 2025.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 493.6M | IPO Year: | 2012 |
| Target Price: | $13.38 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.19 - $11.24 | Next Earning Date: | 11-04-2025 |
| Revenue: | $2,137,000 | Revenue Growth: | -78.63% |
| Revenue Growth (this year): | 79.32% | Revenue Growth (next year): | 413.52% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bunn Paul A. | VSTM | Director | Oct 9 '25 | Sell | $9.06 | 8,333 | $75,496.98 | 8,333 | |
| Calkins Daniel | VSTM | Chief Financial Officer | Sep 24 '25 | Sell | $9.23 | 25 | $230.75 | 109,838 | |
| Calkins Daniel | VSTM | Chief Financial Officer | Sep 22 '25 | Sell | $9.08 | 57 | $517.56 | 109,838 | |
| Gagnon Robert E. | VSTM | Director | Sep 16 '25 | Sell | $9.99 | 281 | $2,807.19 | 41,961 | |
| Stuglik Brian M | VSTM | Director | Sep 16 '25 | Sell | $9.99 | 587 | $5,864.13 | 101,739 | |
| Paterson Dan | VSTM | President and CEO | Sep 16 '25 | Sell | $9.99 | 390 | $3,896.10 | 442,117 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Zacks
6 days ago
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Business Wire
6 days ago
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Simply Wall St.
8 days ago
Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update
Zacks
8 days ago
Best Momentum Stocks to Buy for Oct. 21
Zacks
8 days ago
New Strong Buy Stocks for Oct. 21: NEM, AS and More
MT Newswires
9 days ago
Verastem Says Median Overall Survival Not Reached in Partner's Phase 1/2 Pancreatic Cancer Study; Shares Fall
Zacks
9 days ago
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.